<DOC>
	<DOCNO>NCT01366391</DOCNO>
	<brief_summary>Metformin one commonly prescribe drug worldwide treatment Type 2 Diabetes . It currently use treatment : polycystic ovary syndrome , gestational diabetes , metabolic syndrome obesity . In patient polycystic ovary syndrome ( PCOS ) adverse side effect frequent cause treatment discontinuation . In every day medical practice lower dose Metformin administer search continuation treatment . However , clinical study support assertion . The objective study monitor correlate therapeutic effect Metformin patient PCOS take daily dos 1500mg 1000mg .</brief_summary>
	<brief_title>Therapeutic Monitoring Metformin Women With Polycystic Ovary Syndrome</brief_title>
	<detailed_description>Patients PCOS diagnosis able attempt inclusion criterion divide two group : administration metformin 500 mg tablet three times/day well 1500 mg/day ( group A ) administration metformin 500 mg tablet twice/day 1000 mg/day ( group B ) . Blood sample collect pharmacokinetic evaluation first day administration 3 month begin treatment . The patient monitor 3 month side effect register . The efficacy treatment analyze biochemical physical evaluation .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Polycystic Ovary Syndrome</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Patients age 18 40 year old , use contraceptive drug insulin sensitize agent 3 month . PCOS diagnosis . Insulin resistance Index Homeostatic model Assessment Formula high 2.5 . Another diseases androgen excess ; Patients history serious adverse reaction hypersensibility medicine ; History presence renal , hepatic gastrointestinal disorder . Continuous use pharmaco , inclusively metformin</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>polycystic ovary syndrome</keyword>
	<keyword>metformin</keyword>
	<keyword>pharmacokinetic</keyword>
</DOC>